Special ReportsAll NewsFDA BriefsOncology IconsThe Targeted PulseVoices from the Field
Conference CoverageConference ListingData Dialogue with the Oncology Brothers
All VideosCase-Based Peer PerspectivesEvolving Paradigms in OncologyExpert Perspective Virtual Tumor BoardInterviewsInvestigator PerspectivesMedical World NewsPersonalized MedicinePivotal Practice Views with the Oncology BrothersPodcastsSpeaking Out
All PublicationsEvolving ParadigmsPeers & Perspectives in OncologyTargeted Therapies in Oncology
CASE-BASED ROUNDTABLEPARTNERS
CME/CEClinical TrialsEventsPrecision Medicine PerspectivesPress ReleasesSponsored ContentTreatment Resources
SUBSCRIBE
BRAIN CANCER
BREAST CANCERBREAST CANCER
GENITOURINARY CANCERSGENITOURINARY CANCERSGENITOURINARY CANCERSGENITOURINARY CANCERS
GENOMIC TESTINGGENOMIC TESTING
GI CANCERSGI CANCERSGI CANCERSGI CANCERSGI CANCERS
GYNECOLOGIC CANCERSGYNECOLOGIC CANCERSGYNECOLOGIC CANCERSGYNECOLOGIC CANCERS
HEAD & NECK CANCERS
HEMATOLOGYHEMATOLOGY
IMMUNOTHERAPYIMMUNOTHERAPY
LEUKEMIASLEUKEMIASLEUKEMIASLEUKEMIAS
LUNG CANCERLUNG CANCERLUNG CANCERLUNG CANCERLUNG CANCER
LYMPHOMASLYMPHOMASLYMPHOMASLYMPHOMAS
MPNs
MULTIPLE MYELOMA
NTRK GENE FUSIONS
SARCOMA
SKIN CANCERSSKIN CANCERS
THYROID CANCERS
Spotlight -
  • Biomarker-Driven Lung Cancer
  • GIST
  • HER2 Breast Cancer
  • Chronic Lymphocytic Leukemia
  • Small Cell Lung Cancer
  • Renal Cell Carcinoma
BRAIN CANCER
BREAST CANCERBREAST CANCER
GENITOURINARY CANCERSGENITOURINARY CANCERSGENITOURINARY CANCERSGENITOURINARY CANCERS
GENOMIC TESTINGGENOMIC TESTING
GI CANCERSGI CANCERSGI CANCERSGI CANCERSGI CANCERS
GYNECOLOGIC CANCERSGYNECOLOGIC CANCERSGYNECOLOGIC CANCERSGYNECOLOGIC CANCERS
HEAD & NECK CANCERS
HEMATOLOGYHEMATOLOGY
IMMUNOTHERAPYIMMUNOTHERAPY
LEUKEMIASLEUKEMIASLEUKEMIASLEUKEMIAS
LUNG CANCERLUNG CANCERLUNG CANCERLUNG CANCERLUNG CANCER
LYMPHOMASLYMPHOMASLYMPHOMASLYMPHOMAS
MPNs
MULTIPLE MYELOMA
NTRK GENE FUSIONS
SARCOMA
SKIN CANCERSSKIN CANCERS
THYROID CANCERS
    • CASE-BASED ROUNDTABLE
    • PARTNERS
    • SUBSCRIBE
Advertisement

Navigating Through the Carboplatin Shortage

May 31, 2023
By Joshua K. Sabari, MD
Video

Joshua K. Sabari, MD, discusses the shortage of carboplatin, its impacts, and how oncologist can still treat patients.

Joshua K. Sabari, MD, pssistant Professor, Department of Medicine at NYU Grossman School of Medicine, and director of High Reliability Organization Initiatives at the Perlmutter Cancer Center, discusses the shortage of the chemotherapy drug, carboplatin, and how oncologists can navigate through it.

0:08 | I think for oncology, specifically thoracic medical oncology and some of the other solid tumors, carboplatin has really been a major issue. We know that carboplatin is a standard-of-care agent in curative intent, adjuvant therapy for thoracic malignancies, as well as ovarian cancer. And this is a drug approved in the metastatic setting in other histologies as well, such as head and neck cancer, breast cancer, colorectal and others.

0:37 | So, thinking about how do we move forward with with, you know, a lower sort of availability, these agents for our patients. So, really, we need to reprioritize non essential use of these therapies, particularly given the limited supply. If there's an alternative agent available for our patients, we should use that agent, right. So, you know, in the metastatic setting, there ar egimens that don't require platinum backbone. For example, a CTLA4 inhibitor and a PD-1 inhibitor, one should consider that as an option to increase the supply of this medication. Another thing to consider is to use other medicines right, where carboplatin may be able to be replaced by cisplatin in patients who are fit, have good renal function obvioulsy, and don't have any hearing issues or hearing loss. We do try to use cisplatin if available over carboplatin.

1:35 | We also know unfortunately that cisplatin is in shortage though at the moment, we also are thinking about increasing the interval between cycles to reduce the total treatment dose when this is acceptable. So, in the adjuvant or curative intent setting, I highly recommend against changing the dosing or the guidelines. But you know, if you look at the ASCO or NCCN guidelines, if the guidelines allow for either a 3-or 4-week infusion, I would recommend considering a 4 week infusion over a 3 week infusion as to allow us to have more supply for our patients.

2:04 | And then clearly, we can minimize waste. Unfortunately, a lot of vials of medication are you know only utilized one time per patient. If we can look at you know, vial optimization, so vial size as well as dose rounding and potential opportunity. We moved away from multi-use vials. But if we could move back towards that in order to save drug, I think that could be a very effective strategy for our patients.

Newsletter

Stay up to date on practice-changing data in community practice.

Subscribe Now!
Recent Videos
Related Content

AI-Powered Pathology Tools May Boost Precision Oncology

AI-Powered Pathology Tools May Boost Precision Oncology

Dylann Cohn-Emery
May 8th 2025
Article

Stuart J. Schnitt, MD, discussed artificial intelligence enhancements roadblocks, and potential integration for cancer diagnostics with Targeted Oncology.

Read More


RP1 and the Future of Oncolytic Therapy in Melanoma

RP1 and the Future of Oncolytic Therapy in Melanoma

Jordyn Sava
May 5th 2025
Article

Mohammed Milhem, MBBS discussed the mechanism of action of RP1, the design and preliminary findings of the IGNYTE trial in melanoma.

Read More


Higher ctDNA Serves as Early Warning for Melanoma Recurrence Risk

Higher ctDNA Serves as Early Warning for Melanoma Recurrence Risk

Sabrina Serani
May 5th 2025
Article

David Polsky, MD, discussed a study showing ctDNA levels before melanoma treatment strongly predict recurrence and its speed, potentially guiding future therapy decisions.

Read More


CBT Benefits Cancer Patients' Mental Health and Treatment Adherence

CBT Benefits Cancer Patients' Mental Health and Treatment Adherence

Sabrina Serani
May 2nd 2025
Article

Sofia Chernoff, PsyD, MSEd, discussed how cognitive behavioral therapy helps cancer patients manage emotional challenges by modifying negative thoughts and behaviors.

Read More


Study Indicates Early Resolution of CRS, Neurological Events After Axi-Cel

Study Indicates Early Resolution of CRS, Neurological Events After Axi-Cel

Jordyn Sava
May 1st 2025
Article

Olalekan O Oluwole, MD, MBBS, discussed a study on cytokine release syndrome and neurological events post axicabtagene ciloleucel in large B-cell lymphoma.

Read More


New Standard of Care? KEYNOTE-689 Results in LA-HNSCC

New Standard of Care? KEYNOTE-689 Results in LA-HNSCC

Jordyn Sava
April 30th 2025
Article

Ravindra Uppaluri, MD, PhD, discussed the KEYNOTE-689 trial, which investigated pembrolizumab in locally advanced head and neck squamous cell carcinoma.

Read More

Related Content

AI-Powered Pathology Tools May Boost Precision Oncology

AI-Powered Pathology Tools May Boost Precision Oncology

Dylann Cohn-Emery
May 8th 2025
Article

Stuart J. Schnitt, MD, discussed artificial intelligence enhancements roadblocks, and potential integration for cancer diagnostics with Targeted Oncology.

Read More


RP1 and the Future of Oncolytic Therapy in Melanoma

RP1 and the Future of Oncolytic Therapy in Melanoma

Jordyn Sava
May 5th 2025
Article

Mohammed Milhem, MBBS discussed the mechanism of action of RP1, the design and preliminary findings of the IGNYTE trial in melanoma.

Read More


Higher ctDNA Serves as Early Warning for Melanoma Recurrence Risk

Higher ctDNA Serves as Early Warning for Melanoma Recurrence Risk

Sabrina Serani
May 5th 2025
Article

David Polsky, MD, discussed a study showing ctDNA levels before melanoma treatment strongly predict recurrence and its speed, potentially guiding future therapy decisions.

Read More


CBT Benefits Cancer Patients' Mental Health and Treatment Adherence

CBT Benefits Cancer Patients' Mental Health and Treatment Adherence

Sabrina Serani
May 2nd 2025
Article

Sofia Chernoff, PsyD, MSEd, discussed how cognitive behavioral therapy helps cancer patients manage emotional challenges by modifying negative thoughts and behaviors.

Read More


Study Indicates Early Resolution of CRS, Neurological Events After Axi-Cel

Study Indicates Early Resolution of CRS, Neurological Events After Axi-Cel

Jordyn Sava
May 1st 2025
Article

Olalekan O Oluwole, MD, MBBS, discussed a study on cytokine release syndrome and neurological events post axicabtagene ciloleucel in large B-cell lymphoma.

Read More


New Standard of Care? KEYNOTE-689 Results in LA-HNSCC

New Standard of Care? KEYNOTE-689 Results in LA-HNSCC

Jordyn Sava
April 30th 2025
Article

Ravindra Uppaluri, MD, PhD, discussed the KEYNOTE-689 trial, which investigated pembrolizumab in locally advanced head and neck squamous cell carcinoma.

Read More

About Us
Advertise
Contact Us
CureToday.com
CancerNetwork.com
OncLive.com
OncNursingNews.com
Do Not Sell My Information
Privacy
Terms & Conditions
Editorial Board
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.